Advanced search×
×
  1. Systems biology approaches in identifying the targets of natural compounds for cancer therapy.

    Current Drug Discovery Technologies 10(2):139 (2013) PMID 23237676

    We will briefly introduce the several systems biology approaches, and will discuss the application of these new technologies for identifying the therapeutic targets of natural compounds for supporting their roles in the prevention and/or treatment of human cancers. Furthermore, identification of the...
  2. miR-23a, a critical regulator of "migR"ation and metastasis in colorectal cancer.

    Cancer Discovery 2(6):489 (2012) PMID 22684455 PMCID PMC3375870

    Jahid and colleagues have shown that miR-23a promotes the transition from indolent to invasive colorectal cancer through inhibition of the MTSS1 tumor suppressor. This study reveals a novel role of miR-23a in the acceleration of colorectal cancer progression.
  3. Resveratrol-induced apoptosis is enhanced in low pH environments associated with cancer.

    Journal Of Cellular Physiology 227(4):1493 (2012) PMID 21678400 PMCID PMC3185178

    We explored whether, acidic pH promotes growth inhibition, apoptosis, and DNA damaging capacity of chemopreventive agent resveratrol. Our results reveal that growth inhibition and internucleosomal DNA fragmentation induced apoptosis in Capan-2 and Panc-28 pancreatic cancer cell lines (and not in nor...
  4. The complexities of obesity and diabetes with the development and progression of pancreatic cancer.

    Biochimica et Biophysica Acta 1815(2):135 (2011) PMID 21129444 PMCID PMC3056906

    Pancreatic cancer (PC) is one of the most lethal malignant diseases with the worst prognosis. It is ranked as the fourth leading cause of cancer-related deaths in the United States. Many risk factors have been associated with PC. Interestingly, large numbers of epidemiological studies suggest that o...
  5. ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast can...

    Molecular Cancer Therapeutics 9(6):1503 (2010) PMID 20515951 PMCID PMC2884079

    We hypothesize that inhibition of c-Src and EGFRs will be an effective therapeutic strategy for triple-negative breast cancer. To test our hypothesis, we used a c-Src-specific inhibitor dasatinib (BMS-354825; Bristol-Myers Squibb) and our newly developed ErbB-inhibitory protein (EBIP), a potential p...
  6. miR-146a suppresses invasion of pancreatic cancer cells.

    Cancer Research 70(4):1486 (2010) PMID 20124483 PMCID PMC2978025

    We report lower expression of miR-146a in pancreatic cancer cells compared with normal human pancreatic duct epithelial cells. Reexpression of miR-146a inhibited the invasive capacity of pancreatic cancer cells with concomitant downregulation of EGFR and the NF-kappaB regulatory kinase interleukin 1...
  7. Exploitation of the Notch signaling pathway as a novel target for cancer therapy.

    Anticancer Research 28(6A):3621 (2008) PMID 19189643

    The Notch signaling pathway appears to be responsible for maintaining a balance between cell proliferation and apoptosis and thus it has been suggested that Notch may play an important role in species development and in the development and progression of several malignancies. Therefore, the Notch si...
  8. Nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL, (-)-Gossypol, enhances biological effect of genistein against BxPC-3 human pancrea...

    Pancreas 31(4):317 (2005) PMID 16258364

    We have previously shown that genistein, a prominent soy isoflavone, transcriptionally down-regulates Bcl-2, Bcl-XL, VEGF, MMP-9, and uPAR via inhibiting NF-kappaB activity. In this study, genistein down-regulated NF-kappaB DNA binding activity and inhibited the growth of BxPC-3 pancreatic cancer ce...
  9. Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines.

    Molecular Cancer Therapeutics 3(11):1421 (2004) PMID 15542781

    We conclude that celecoxib potentiates gemcitabine-induced growth inhibition and apoptosis in pancreatic cell lines. In addition to inhibition of the COX-2 enzyme, the celecoxib and gemcitabine combination down-regulated nuclear factor-kappaB activation, which in turn may have contributed to the ind...
  10. Effects of lycopene supplementation in patients with localized prostate cancer.

    Experimental Biology and Medicine 227(10):881 (2002) PMID 12424329

    We conducted a clinical trial to investigate the biological and clinical effects of lycopene supplementation in patients with localized prostate cancer. Twenty-six men with newly diagnosed prostate cancer were randomly assigned to receive a tomato oleoresin extract containing 30 mg of lycopene (n =...